SABRINA ARNOLD: Open Payments
NPI 1811608029 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,508 in 139 payments from 18 companies in 2025. Trend: 2023 $1,200 · 2024 $1,445 · 2025 $2,508
Food & beverage: $2,429Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 30 | $545 |
| Viatris Specialty LLC | 16 | $308 |
| GlaxoSmithKline, LLC. | 27 | $298 |
| Grifols USA, LLC | 7 | $196 |
| Regeneron Healthcare Solutions, Inc. | 13 | $189 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| GENZYME CORPORATION | 8 | $154 |
| United Therapeutics Corporation | 3 | $99 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
Products named: DUPIXENT, YUPELRI, FASENRA, Prolastin-C Liquid, GLASSIA, BREZTRI, NUCALA, TEZSPIRE.
Industry payments across AR — which companies pay providers there.
